April 24, 2015 (Shareholders Foundation) - An investigation on behalf of investors of Aerie Pharmaceuticals Inc (NASDAQ:AERI) shares over potential securities laws violations by Aerie Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Aerie Pharmaceuticals Inc (NASDAQ:AERI) concerning whether a series of statements by Aerie Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) grew from $10.50 per share in late 2013 to as high as $35.60 per share on April 23, 2015.

Then on April 23, 2015, after the market closed, Aerie Pharmaceuticals Inc reported the results of its first Phase 3 registration trial (Rocket 1) for Rhopressa, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Aerie Pharmaceuticals Inc said that the trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily Rhopressa compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.

Shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) declined from over$35.00 per share on April 23, 2015, to under $14 per share on April 24, 2015.